Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07090499 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 4 → 5 primary endpoints
See other at-risk trials from Pfizer

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Primary endpoint(s) modified Show 5 more changesShow less
    • Interventions modified
    • Trial arms changed: 3 → 8
    • Eligibility criteria expanded, about 43 words
    • Secondary endpoints: details revised at 1 of 10 entries
    • Site details revised at 6 of 31 sites
  3. Enrollment increased: 310 → 540 participants
    • Study sites: 30 to 31
    v8
  4. Study sites: 28 to 30v7
  5. Site details revised at 3 of 28 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 13 to 28v5
  2. Study sites: 2 to 13v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 2
    • Primary completion date: Aug 19, 2028 to Jul 8, 2028
    • Study completion date: Aug 19, 2029 to Jul 8, 2029
    • Start date changed from estimate of Aug 7, 2025 to Aug 20, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,078 trials monitored
See 172 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
and 3 more diseases
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules. In the second part of the study, groups of people will receive the study drug in dosing regimens deemed to be safe in Part 1. In the third part of the study, people will receive the study drug together with other anti-cancer medicines.
Trial Details
NCT Number NCT07090499
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer +5 more
Related terms Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Pancreatic Neoplasms, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms
Enrollment 540 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov